Holen Sie sich die Stockscreener-App
18.16
1.36%
-0.25
Handel nachbörslich:
18.00
-0.16
-0.88%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$18.41
Offen:
$18.33
24-Stunden-Volumen:
5.05M
Relative Volume:
0.55
Marktkapitalisierung:
$9.38B
Einnahmen:
$11.24B
Nettoeinkommen (Verlust:
$-900.00M
KGV:
-10.82
EPS:
-1.679
Netto-Cashflow:
$323.00M
1W Leistung:
-2.94%
1M Leistung:
+8.61%
6M Leistung:
-21.11%
1J Leistung:
-40.28%
1-Tages-Spanne:
$17.89
$18.48
1-Wochen-Bereich:
$17.89
$19.18
52-Wochen-Spanne:
$15.73
$32.68
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
18.16 | 9.50B | 11.24B | -900.00M | 323.00M | -1.679 |
ISRG
Intuitive Surgical Inc
|
482.22 | 169.58B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
152.14 | 44.05B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.76 | 39.09B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.80 | 36.98B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
219.85 | 31.98B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Baxter International (BAX) Projected to Post Earnings on Thursday - MarketBeat
BAX (Baxter International Inc.) notches 5.7 percent Q4 2025 revenue growth as shares trade slightly higher despite EPS miss.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Baxter International Inc. stock underperforms Thursday when compared to competitors - MSN
Baxter International earnings preview: What to expect - MSN
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pzena shows 65.35M Baxter (NYSE: BAX) shares; 12.7% ownership - Stock Titan
Baxter International - Forbes
Baxter International Prepares Fiscal Q1 2026 Earnings Amid Profit Drop - HarianBasis.co
BAX Stock Price, Quote & Chart | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Smart Money is Buying Baxter International Inc. (BAX) - The Acquirer's Multiple
Baxter (BAX) Stock: Is It a Compelling Buy (Investor Interest) 2026-04-20Earnings Breakout - Cổng thông tin điện tử tỉnh Lào Cai
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
Baxter International Inc. (BAX) Stock Analysis: Exploring an 18.20% Potential Upside Amidst Healthcare Growth - DirectorsTalk Interviews
Baxter International Earnings Preview: What to Expect - Yahoo Finance
Assessing Baxter International (BAX) Valuation After New Surgical Table And Smart Stretcher Unveiling - Sahm
Baxter International (BAX) Q4 earnings lag estimates - MSN
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Is It Too Late to Buy Baxter International Inc (BAX) After 3.1% Rally? GF Value Says Undervalued - GuruFocus
Is It Time To Reassess Baxter International (BAX) After A 35.9% One Year Share Price Slide - Yahoo Finance
Blood And Blood Components Market Is Booming So Rapidly | Baxter - openPR.com
Baxter International Inc. stock (US0673431090): Why does its hospital supply edge matter more now fo - AD HOC NEWS
Tiffany Zack joins Baxter as director of sustainability - Medical Buyer
Baxter International Inc stock (US0718131099): Is its medtech stability the real edge in uncertain m - AD HOC NEWS
Baxter Showcases Recent Innovations at AORN Global Surgical Conference and Expo 2026 - marketscreener.com
Baxter Welcomes Tiffany Zack as Director of Sustainability - Healthcare Digital
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026 - National Today
Baxter Highlights New Surgical and Patient Support Products - National Today
BAX Showcases Innovative Products at Global Surgical Conference - GuruFocus
Will Baxter’s New IV Automation Tool Subtly Reshape Its Patient Safety Edge and Valuation Story (BAX)? - Sahm
Gap Down: Is Baxter International Inc a cyclical or defensive stockQuarterly Growth Report & Growth Focused Investment Plans - baoquankhu1.vn
Short Squeeze: Is Baxter International Inc a cyclical or defensive stock2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Baxter Launches Pilot Program for Therapy Animals in Healthcare Settings - respiratory-therapy.com
Baxter International Provides FY 2026 Earnings Guidance - National Today
Baxter (NYSE: BAX) exec holds 31K shares plus 25.9K options - Stock Titan
Baxter (NYSE: BAX) surgery chief lists common shares and option grants - Stock Titan
[Form 3] BAXTER INTERNATIONAL INC Initial Statement of Beneficial Ownership - Stock Titan
J&J Defends Blood-Clotting Powder IP From Baxter Attack - Law360
Alpha Buying: Following Conviction, Not the CrowdAvantor (NYSE:AVTR), Baxter International (NYSE:BAX) - Benzinga
Robotic Pharmacy Prescription Market Research and Global Forecast Report 2025-2032 - GlobeNewswire Inc.
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors - marketscreener.com
Baxter schedules April 30 webcast for first-quarter 2026 results - Stock Titan
Baxter International Inc (BAX) Stock Price, Trades & News - GuruFocus
Medical Syringe Market Is Booming So Rapidly Growth by 2033| - openPR.com
Hologic hires former Baxter International chief as next CEO - Radiology Business
Former Baxter chief takes helm at Marlborough medical device maker - The Business Journals
Baxter International Inc. (BAX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evercore ISI Group Lowers Price Target for Baxter International (BAX) to $22 | BAX Stock News - GuruFocus
Fund Update: 3,614,465 BAXTER INTERNATIONAL (BAX) shares added to GREENHAVEN ASSOCIATES INC portfolio - Quiver Quantitative
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings - Bioscience Association Manitoba
Evercore ISI Adjusts Baxter International Price Target to $22 From $23, Maintains Outperform Rating - marketscreener.com
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):